Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Haematologica|February 18, 2014
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice dailyTimothy P Hughes, Andreas Hochhaus, Hagop M Kantarjian, et al.
The Journal of Allergy and Clinical Immunology|May 22, 2020
Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosisKarin Hartmann, Jason Gotlib, Cem Akin, et al.
Blood|March 14, 2015
Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchinaJianxiang Wang, Zhi-Xiang Shen, Giuseppe Saglio, et al.
European Journal of Cancer (Oxford, England : 1990)|August 28, 2010
The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinomaManfred Johannsen, Gianluca Spitaleri, Giuseppe Curigliano, et al.
Cell Adhesion & Migration|January 7, 2015
The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancerChiara Catania, Michela Maur, Rossana Berardi, et al.
The Lancet. Haematology|December 8, 2023
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trialAmer M Zeidan, Kiyoshi Ando, Odile Rauzy, et al.
Molecular Cancer Research : MCR|April 18, 2023
MDM2 Inhibition Enhances Immune Checkpoint Inhibitor Efficacy by Increasing IL15 and MHC Class II ProductionMarlene Langenbach, Sophie Giesler, Stefan Richtsfeld, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 4, 2025
Isolated oral CD30+/CD4+ CAR+ T-cell lymphoma in long-term remission after radiotherapyEvandro Bezerra, Ludmila Lupu, Marcos de Lima, et al.
The New England Journal of Medicine|November 26, 2024
Aggressive Lymphoma after CD19 CAR T-Cell TherapyGuido Kobbe, Monika Brüggemann, Ben-Niklas Baermann, et al.
Blood|July 19, 2022
Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulationJenny N H G Ho, Dominik Schmidt, Theresa Lowinus, et al.
Pageof 4